Corvus Pharmaceuticals, Inc.
CRVS
$6.94
-$0.31-4.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.32% | 15.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.41% | 22.42% | |||
| Operating Income | -3.41% | -22.42% | |||
| Income Before Tax | -152.64% | 225.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -152.64% | 225.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -152.64% | 225.43% | |||
| EBIT | -3.41% | -22.42% | |||
| EBITDA | -3.34% | -22.45% | |||
| EPS Basic | -148.81% | 218.85% | |||
| Normalized Basic EPS | -148.82% | 218.86% | |||
| EPS Diluted | 22.24% | 25.40% | |||
| Normalized Diluted EPS | -150.87% | 214.08% | |||
| Average Basic Shares Outstanding | 7.83% | 5.53% | |||
| Average Diluted Shares Outstanding | 3.49% | 9.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||